Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 10.57% | 9.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.57% | 9.07% | |||
| Cost of Revenue | -2.55% | -1.23% | |||
| Gross Profit | 22.18% | 20.17% | |||
| SG&A Expenses | 0.92% | -0.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.10% | -0.41% | |||
| Operating Income | 40.68% | 23.09% | |||
| Income Before Tax | 40.67% | 32.98% | |||
| Income Tax Expenses | -257.48% | -65.51% | |||
| Earnings from Continuing Operations | 49.85% | 35.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 49.85% | 35.56% | |||
| EBIT | 40.68% | 23.09% | |||
| EBITDA | 48.24% | 26.55% | |||
| EPS Basic | 50.16% | 35.95% | |||
| Normalized Basic EPS | 46.61% | 26.54% | |||
| EPS Diluted | 50.16% | 37.40% | |||
| Normalized Diluted EPS | 46.61% | 26.54% | |||
| Average Basic Shares Outstanding | 0.69% | 0.59% | |||
| Average Diluted Shares Outstanding | 0.69% | 0.59% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||